Ultime notizie per Black Cat Syndicate (OTC:BLCAF) Azioni

Black Cat Syndicate Ltd is a mining company. It focuses on the exploration and development of the goldfield project. The company is engaged in the exploration and development of the Bulong Gold Field project located to the east of Kalgoorlie. The company is organized into two operating segments, being mine development assets and exploration and evaluation assets, all conducted within Western Australia. The company's project includes Kal East Gold project, Coyote Gold Operation, Paulsens Gold Operation.

Black Cat Syndicate Ltd

Barclays analyst Tim Long maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Overweight and raises the price target from $341 to $495.

News

Price Target

Analyst Ratings

ANET

Barclays Maintains Overweight on Arista Networks, Raises Price Target to $495

Raymond James analyst David Feaster reiterates VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) with a Outperform and raises the price target from $15 to $17.

Reiteration

VBNK

Raymond James Reiterates Outperform on VersaBank, Raises Price Target to $17

Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) is betting big on its upcoming Gravity SUV to capture a broader slice of the electric vehicle (EV) market, but it's a <a href="https://www.benzinga.com/quote/LCID/news">cautious play for investors</a>. 
Needham's Chris Pierce reaffirmed a Hold rating on LCID stock, highlighting promising delivery gains while flagging concerns over long-term profitability and further dilution risks.
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Lucid&#8217;s Rising Deliveries, Falling Margins</h2>
Lucid's latest earnings report spotlighted a third consecutive quarter of record deliveries, a rare positive amid the fierce EV competition. The company is using pricing adjustments to fuel this demand, but Pierce noted that discounts have chipped away at the average selling price for five straight quarters.
Despite these pricing moves, Lucid still hasn't cracked the code to profitability—a challenge, as EV giants with delivery volumes five times higher still struggle to achieve positive gross margins, the analyst said.
Read Also: <a href="https://www.benzinga.com/24/11/41838253/lucid-rises-nearly-5-in-pre-market-after-strong-q3-results-opening-orders-for-gravity-suv">Lucid Rises Nearly 5% In Pre-Market After Strong Q3 Results, Opening Orders For Gravity SUV</a>
<h2 class="wp-block-heading">Gravity SUV: A Game Changer Or A Gamble?</h2>
Lucid's Gravity SUV, set for production later this year, represents a significant push to broaden its brand reach. Positioned as Lucid's gateway into the lucrative SUV category, Gravity is expected to expand the company's addressable market. Pierce described it as a "second chance at a first impression" for the brand, although he tempered expectations with a cautious rollout projection, with substantial deliveries not expected until the latter half of 2026.
While Lucid boasts cutting-edge tech that differentiates it from competitors, Pierce noted that the company has yet to achieve strong consumer resonance—a sentiment dampened by slowing EV adoption rates across the industry.
<h2 class="wp-block-heading">The Dilution Dilemma</h2>
Backed by the deep-pocketed Saudi Public Investment Fund (PIF), Lucid has managed to secure substantial funding for its ambitious roadmap. 
However, Pierce foresees additional capital raises—potentially up to $4 billion—necessary to bridge the gap to profitability and push Gravity into the market. For shareholders, this could spell further dilution, with Lucid already leaning on a recent $1.75 billion raise to power through the SUV launch and into 2026, the analyst noted.
<h2 class="wp-block-heading">LCID Chart: The Bulls Hold Out Hope</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122427/Screenshot-2024-11-08-at-10.54.09-PM.png" alt="" class="wp-image-638165" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122427/Screenshot-2024-11-08-at-10.54.09-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122427/Screenshot-2024-11-08-at-10.54.09-PM-300x216.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
Lucid's stock has recently been trading below key moving averages, with the eight, 20-day, and 50-day simple moving averages (SMA) all signaling a bearish trend. The MACD indicator is reinforcing the bearish momentum at a negative 0.29, signaling short-term pessimism.
With the Relative Strength Index (RSI) in oversold territory at 27.17, caution is warranted as investors assess Lucid's extended path to profitability.
Lucid may be cruising forward with promising delivery numbers and an enticing new SUV, but as Needham's Pierce advises, the road to profitability remains long and uncertain. 
For now, it's a waiting game as investors weigh the allure of Lucid's Gravity against the gravitational pull of profitability challenges and potential dilution.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41826774/lucid-q3-earnings-revenue-beat-eps-beat-on-track-to-produce-9k-vehicles-in-2024">Lucid Q3 Earnings: Revenue Beat, EPS Beat, On Track To Produce 9K Vehicles In 2024</a></li>
</ul>
Photo by Mike Mareen on Shutterstock

Analyst Color

Long Ideas

Technicals

Tech

Trading Ideas

LCID

Lucid's Delivery Gains, New SUV Can't Shake Profit Concerns

Raymond James analyst Rick Patel reiterates Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and raises the price target from $55 to $57.

Raymond James Reiterates Outperform on Tapestry, Raises Price Target to $57

Barclays analyst Raimo Lenschow maintains Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) with a Underweight and raises the price target from $29 to $34.

APPN

Barclays Maintains Underweight on Appian, Raises Price Target to $34

<ul>
<li>Data continues positive trend as additional patients are enrolled in 3 cohorts</li>
<li>Vaccine was safe and well tolerated by participants in all 3 cohorts</li>
<li>Protocol defined immune responses were exhibited in over 70% of patients</li>
<li>A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025</li>
</ul>
SAN JOSE, Calif., Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4297993-1&amp;h=2144968050&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04674306&amp;a=NCT04674306">NCT04674306</a>) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense. The presentation, titled "Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC," was presented by Dr. Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic.&nbsp;

Biotech

General

ANIX

Anixa Biosciences And Cleveland Clinic Present New Updated Data From Phase 1 Study Of Breast Cancer Vaccine At The 39th SITC Annual Meeting; Protocol Defined Immune Responses Were Exhibited In Over 70% Of Patients

Barclays analyst Betty Jiang maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Equal-Weight and lowers the price target from $30 to $27.

Barclays Maintains Equal-Weight on APA, Lowers Price Target to $27

RBC Capital analyst Rishi Jaluria maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $250 to $275.

VEEV

RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $275

Barclays analyst Mario Lu maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and raises the price target from $100 to $110.

ABNB

Barclays Maintains Underweight on Airbnb, Raises Price Target to $110

<a href="https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3" title="https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3">https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3</a>

Legal

OTTR

'DoJ Investigates Potential Price-Fixing In PVC Pipe Market' - Financial Times

Editor&#8217;s note: This story has been updated with additional comments tweeted by Bill Ackman. 
Billionaires are lining up to serve in President-elect Donald Trump&#8216;s <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">incoming administration</a>, especially those eager to <a href="https://www.benzinga.com/news/24/08/40146910/does-donald-trumps-proposed-tax-cut-threaten-social-security-and-medicare-heres-what-think-tanks-war">cut federal assistance programs</a>.
Bill Ackman is one of them. 
On Friday morning, when a user on X asked whether the Pershing Square Capital founder would &#8220;consider joining Elon [Musk] in the Department of Government Efficiency,&#8221; Ackman <a href="https://x.com/BillAckman/status/1854891084381377017">replied</a> with a single word: &#8220;Yes.&#8221;
Musk has proposed the idea of creating a &#8220;Department of Government Efficiency.&#8221; This hypothetical agency would slash federal spending by the trillions. Should such a plan come to fruition, analysts suggest programs like health care, food security and housing <a href="https://www.benzinga.com/startups/24/11/41750727/kevin-oleary-supports-elon-musks-2-trillion-plan-to-slash-government-spending-with-trumps-backing-it">would be gutted</a>. 
Trump was receptive to this idea. 
See Also: <a href="https://www.benzinga.com/news/24/07/39657200/ex-trump-staffer-shares-texts-to-prove-that-ex-presidents-campaign-settled-to-keep-discrimination-an">Ex-Trump Staffer Shares Texts To Prove That Ex-President&#8217;s Campaign Settled To Keep Sexual Harassment Lawsuits Quiet</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yes
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1854891084381377017?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ackman is among Trump&#8217;s most ardent Wall Steet supporters. The billionaire told CNBC that he&#8217;s unfazed by the <a href="https://www.benzinga.com/government/24/11/41828468/trump-says-hed-replace-income-taxes-with-tariffs-the-potential-economic-fallout">potential market implications</a> of a second Trump administration.
In a follow-up tweet, Ackman said he is not leaving his day job for one with the Trump administration.
&#8220;Like Elon Musk who has a half a dozen full-time jobs, I would be delighted to help anyway that I can to help DOGE succeed,&#8221; Ackman tweeted. 
Musk contributed nine-digit sums to Trump&#8217;s campaign and organized much of Trump&#8217;s ground game.
The Tesla Inc. CEO has also openly said Americans will experience &#8220;temporary hardship&#8221; once federal cuts are made.
According to the U.S. Treasury, the country&#8217;s federal budget was $6.75 trillion in 2024. Musk&#8217;s proposal to make large cuts to the federal budget would necessitate shedding several categories. Analysts put social security, military spending, Medicare, and veterans benefits on that list.
It remains to be seen how high of a legislative priority this will be for Trump.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41843182/fed-cuts-rates-but-inflation-remains-elephant-in-the-room">Fed Cuts Interest Rates, But Inflation Remains Elephant In The Room</a></li>
</ul>
Image: Shutterstock

Government

Health Care

Politics

Bill Ackman Says He'd Consider Joining Elon Musk's 'Department Of Government Efficiency' Under Trump (UPDATED)

XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares are trading relatively flat on Friday after the company <a href="https://www.benzinga.com/pressreleases/24/11/g41841998/xpeng-unveils-the-p7-worlds-first-ai-defined-vehicle-redefining-premium-and-intelligent-driving">hosted its XPENG AI Day event.</a>
According to&nbsp;<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, XPEV stock has lost over 11% in the past year. Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Kensho Smart Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>).
On November 7, the company officially launched the XPENG P7+, <a href="https://www.benzinga.com/pressreleases/24/11/g41843762/xpeng-unveils-kunpeng-super-electric-system-and-ai-defined-mobility-innovations-at-xpeng-ai-day">the world&#8217;s first AI-defined vehicle, in China.</a>
XPeng has also launched the Kunpeng Super Electric System, an advanced 800V high-voltage platform with &#8220;ultra-fast&#8221; charging and AI-powered optimization. 
The system has a 430 km pure electric range and over 1,400 km combined range, with the ability to add 1 km of range per second during charging, per a press release.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/11/41846732/kars-etf-hits-golden-cross-powered-by-tesla-geely-xpeng-li">KARS ETF Hits Golden Cross Powered By Tesla, Geely, Xpeng, Li</a>
XPeng said that the system includes an &#8220;ultra-quiet&#8221; range extender and a battery management system that extends lifespan by 30%.
These apart, XPeng also unveiled major advancements in autonomous driving, flying cars, and AI robotics. The company's Ultra model Robotaxi features L4-level autonomy, Turing chips, and 3,000T of processing power.
The XPeng AEROHT flying car is a modular design with simple controls, set for its first public flight in November and pre-orders in December.
Additionally, XPeng&#8217;s AI Robot Iron, a humanoid robot with over 60 joints, is already in use for internal operations like factories and stores.
Chairman He Xiaopeng highlighted XPeng&#8217;s commitment to AI innovation as a key factor in driving future mobility.
Price Action: XPEV shares are trading lower by 0.11 to $14.21 at last check Friday.
Photo by Koshiro K on Shutterstock
Read Also:&nbsp;
<a href="https://www.benzinga.com/news/24/01/36508540/what-does-gms-electric-future-look-like-after-chevrolet-bolts-exit-last-years-delivery-numbers-could" target="_blank" rel="noreferrer noopener">What Does GM's Electric Future Look Like After Chevrolet Bolt's Exit? Last Year's Delivery Numbers Could Give A Hint</a>

Equities

Markets

Movers

HAIL

XPEV

What's Going On With XPeng Stock Friday?

Raymond James analyst Brian Peterson maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Strong Buy and lowers the price target from $52 to $50.

Raymond James Maintains Strong Buy on RingCentral, Lowers Price Target to $50

Barclays analyst Duffy Fischer maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Equal-Weight and raises the price target from $295 to $315.

Barclays Maintains Equal-Weight on Air Products & Chemicals, Raises Price Target to $315

RBC Capital analyst Daniel Perlin maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Sector Perform and raises the price target from $27 to $40.

TOST

RBC Capital Maintains Sector Perform on Toast, Raises Price Target to $40

Raymond James analyst Rick Patel maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $215 to $235.

Raymond James Maintains Outperform on Ralph Lauren, Raises Price Target to $235

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why
Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with hematological malignancies and solid tumors.
The company's lead asset, Zynlonta (loncastuximab tesirine-Ipyl), is a CD19-directed ADC with a pyrrolobenzodiazepine (PBD) payload.
The drug received accelerated FDA approval in January 2021 for adult patients with relapsed/refractory (r/r) large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Also Read:&nbsp;<a href="https://www.benzinga.com/general/biotech/23/07/33324772/adc-therapeutics-pulls-plug-on-mid-stage-zynlonta-study-in-untreated-lymphoma-patients-after-pati">ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths</a>
The analyst points out that Zynlonta has faced stiff competition, and while it reached an annualized revenue run rate of about $80 million at its peak in the first quarter of 2023, it has struggled in the market.
The analyst expects Zynlonta&#8217;s peak revenue in the third-line treatment setting to reach $110 million in the U.S. by 2032.
The analyst&#8217;s outlook depends on the expectation that Zynlonta will receive approval for use in second-line treatment for diffuse large B-cell lymphoma (DLBCL), based on positive results from the LOTIS-5 and LOTIS-7 clinical trials.
Preclinical data suggests that combining Zynlonta with rituximab, an anti-CD20 antibody, may improve tumor control and provide longer-lasting results. The company is looking to expand Zynlonta&#8217;s use to treat second-line DLBCL and indolent lymphomas, either alone or in combination with other treatments.
Although the analyst supports Zynlonta's approval for second-line DLBCL, they are cautious about its revenue potential in this space.
Stephens has initiated with an Overweight rating, <a href="https://www.benzinga.com/quote/ADCT/analyst-ratings">with a price target of $6</a>.
The second-line DLBCL market is competitive with many treatment options available. However, the analyst sees value in Zynlonta due to its promising efficacy, with an 80% overall response rate and a 50% complete response rate. They estimate that Zynlonta could contribute about $172 million in revenue from second-line DLBCL by 2032.
In addition, ADCT has a broad pipeline of antibody-drug conjugates (ADCs) targeting other solid tumor indications, giving the company multiple opportunities for growth outside of Zynlonta.
Price Action: ADCT stock is up 0.68% at $2.95 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook">Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook</a></li>
</ul>

Initiation

ADCT

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $58 to $60.

TNDM

Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $60

Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Equal-Weight and raises the price target from $19 to $21.

PRVA

Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $21

Raymond James analyst Joseph Altobello maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Strong Buy and raises the price target from $92 to $110.

Comments

Black Cat Syndicate

Notizie

Ultime notizie per Black Cat Syndicate (OTC:BLCAF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO